Gene:
MAPK3
mitogen-activated protein kinase 3

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  PRKM3
Alternate Symbols:  ERK1; p44erk1; p44mapk
PharmGKB Accession Id: PA30622

Details

Cytogenetic Location: chr16 : p11.2 - p11.2
GP mRNA Boundary: chr16 : 30125426 - 30134630
GP Gene Boundary: chr16 : 30122426 - 30144630
Strand: minus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. ACE Inhibitor Pathway, Pharmacodynamics
    Model, non-tissue-specific cell displaying genes which may be involved in the ACE inhibitor pathway
  1. Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics
    Genes involved in the pharmacodynamics of the drugs that act on the renin-angiotensin-aldosterone system.
  1. Diuretics Pathway, Pharmacodynamics
    Diagrammatic representation of candidate genes involved in the pharmacodynamics of diuretics in a stylized kidney cell.
  1. EGFR Inhibitor Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes that may be involved in the treatment using epidermal growth factor receptor specific tyrosine kinase inhibitors or monoclonal antibodies.
  1. Sorafenib Pharmacodynamics
    Mechanism of action of sorafenib
  1. VEGF Signaling Pathway
    Model endothelial cell displaying genes of the VEGF signalling pathway and the sites at which bevacizumab, sorafenib, sunitinib, brivanib and cilengitide are known to act.

Curated Information ?

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
isoproterenol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
sorafenib
Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Beta Blocking Agents

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Asthma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neoplasms

Publications related to MAPK3: 5

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer research. 2004. Wilhelm Scott M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Distinct roles for Src tyrosine kinase in beta2-adrenergic receptor signaling to MAPK and in receptor internalization. The Journal of biological chemistry. 2004. Huang Jianyun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. The Biochemical journal. 2003. Shenoy Sudha K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Airway wall remodelling and hyperresponsiveness: modelling remodelling in vitro and in vivo. Pulmonary pharmacology & therapeutics. 2001. Stewart A G. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. The Journal of biological chemistry. 1997. Kroll J, et al. PubMed

LinkOuts

NCBI Gene:
5595
OMIM:
601795
RefSeq RNA:
NM_001040056
NM_001109891
NM_002746
RefSeq Protein:
NP_001035145
NP_001103361
NP_002737
RefSeq DNA:
NT_010393
ALFRED:
LO073680Y
HuGE:
MAPK3
Comparative Toxicogenomics Database:
5595
ModBase:
P27361
HumanCyc Gene:
HS02421
HGNC:
6877

Common Searches